Drug Profile
Romiplostim biosimilar - Intas Pharmaceuticals
Latest Information Update: 13 Jul 2022
Price :
$50
*
At a glance
- Originator Intas Biopharmaceuticals
- Class Antianaemics; Carrier proteins; Immunotherapies; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Thrombopoietin receptor agonists; Thrombopoietin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Idiopathic thrombocytopenic purpura
Most Recent Events
- 18 Feb 2022 No development reported - Phase-III for Idiopathic thrombocytopenic purpura in India (SC)
- 30 Apr 2018 Intas Pharmaceuticals initiates a phase I trial for Idiopathic Thrombocytopenic Purpura in India (SC) (CTRI/2017/11/010620)
- 04 Jan 2018 Intas Pharmaceuticals plans a phase I trial for Idiopathic Thrombocytopenic Purpura in India , (CTRI/2017/11/010620)